NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Zillow Group, Inc. (NASDAQ:Z), Genpact Limited (NYSE:G), Royal Caribbean Cruises Ltd. (NYSE:RCL), CommScope Holding Company, Inc. (NASDAQ:COMM), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), and E.W. Scripps Company (NASDAQ:SSP), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
Z DOWNLOAD: http://Capital-Review.com/register/?so=Z
G DOWNLOAD: http://Capital-Review.com/register/?so=G
RCL DOWNLOAD: http://Capital-Review.com/register/?so=RCL
COMM DOWNLOAD: http://Capital-Review.com/register/?so=COMM
INO DOWNLOAD: http://Capital-Review.com/register/?so=INO
SSP DOWNLOAD: http://Capital-Review.com/register/?so=SSP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Zillow Group, Inc. (NASDAQ:Z), Genpact Limited (NYSE:G), Royal Caribbean Cruises Ltd. (NYSE:RCL), CommScope Holding Company, Inc. (NASDAQ:COMM), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), and E.W. Scripps Company (NASDAQ:SSP) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ZILLOW GROUP, INC. (Z) REPORT OVERVIEW
Zillow Group's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Zillow Group reported revenue of $365.34MM vs $282.33MM (up 29.40%) and analysts estimated basic earnings per share -$0.49 vs -$0.41. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Zillow Group reported revenue of $1,333.55MM vs $1,076.79MM (up 23.84%) and analysts estimated basic earnings per share -$0.61 vs -$0.51. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019.
To read the full Zillow Group, Inc. (Z) report, download it here: http://Capital-Review.com/register/?so=Z
-----------------------------------------
GENPACT LIMITED (G) REPORT OVERVIEW
Genpact's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Genpact reported revenue of $835.34MM vs $734.41MM (up 13.74%) and analysts estimated basic earnings per share $0.41 vs $0.35 (up 17.14%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Genpact reported revenue of $3,000.79MM vs $2,736.93MM (up 9.64%) and analysts estimated basic earnings per share $1.48 vs $1.36 (up 8.82%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.37. The estimated EPS forecast for the next fiscal year is $1.93 and is expected to report on February 6th, 2020.
To read the full Genpact Limited (G) report, download it here: http://Capital-Review.com/register/?so=G
-----------------------------------------
ROYAL CARIBBEAN CRUISES LTD. (RCL) REPORT OVERVIEW
Royal Caribbean Cruises' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Royal Caribbean Cruises reported revenue of $2,332.30MM vs $2,004.47MM (up 16.36%) and analysts estimated basic earnings per share $1.49 vs $1.34 (up 11.19%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Royal Caribbean Cruises reported revenue of $9,493.85MM vs $8,777.85MM (up 8.16%) and analysts estimated basic earnings per share $8.60 vs $7.57 (up 13.61%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.09. The estimated EPS forecast for the next fiscal year is $11.04 and is expected to report on January 29th, 2020.
To read the full Royal Caribbean Cruises Ltd. (RCL) report, download it here: http://Capital-Review.com/register/?so=RCL
-----------------------------------------
COMMSCOPE HOLDING COMPANY, INC. (COMM) REPORT OVERVIEW
CommScope Holding's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, CommScope Holding reported revenue of $1,057.73MM vs $1,120.43MM (down 5.60%) and basic earnings per share -$0.12 vs $0.28. For the twelve months ended December 31st, 2018 vs December 31st, 2017, CommScope Holding reported revenue of $4,568.51MM vs $4,560.58MM (up 0.17%) and analysts estimated basic earnings per share $0.73 vs $1.01 (down 27.72%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.45. The estimated EPS forecast for the next fiscal year is $3.10 and is expected to report on February 20th, 2020.
To read the full CommScope Holding Company, Inc. (COMM) report, download it here: http://Capital-Review.com/register/?so=COMM
-----------------------------------------
INOVIO PHARMACEUTICALS, INC. (INO) REPORT OVERVIEW
Inovio Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Inovio Pharmaceuticals reported revenue of $2.50MM vs $8.79MM (down 71.52%) and analysts estimated basic earnings per share -$0.35 vs -$0.25. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Inovio Pharmaceuticals reported revenue of $30.48MM vs $42.22MM (down 27.80%) and analysts estimated basic earnings per share -$1.05 vs -$1.08. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.36. The estimated EPS forecast for the next fiscal year is -$1.07 and is expected to report on March 10th, 2020.
To read the full Inovio Pharmaceuticals, Inc. (INO) report, download it here: http://Capital-Review.com/register/?so=INO
-----------------------------------------
E.W. SCRIPPS COMPANY (SSP) REPORT OVERVIEW
E.W. Scripps' Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, E.W. Scripps reported revenue of $368.11MM vs $261.75MM (up 40.64%) and analysts estimated basic earnings per share $0.29 vs $0.08 (up 262.50%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, E.W. Scripps reported revenue of $1,208.43MM vs $876.97MM (up 37.80%) and analysts estimated basic earnings per share $0.25 vs -$0.16. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is $1.24 and is expected to report on March 6th, 2020.
To read the full E.W. Scripps Company (SSP) report, download it here: http://Capital-Review.com/register/?so=SSP
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.